"We have a growth strategy in the regions for which SCENESSE®is an approved treatment. In Europe, SCENESSE®has been accepted as standard of care with coverage from government and private payors and insurance firms. We are working on reimbursement agreements to distribute SCENESSE®for EPP in more European countries, expanding the number of Expert Centers, and increasing patient treatment access. In the USAwe completed the key pre-distribution logistics within six months of FDA approval and facilitated first treatment in April 2020, amidst the global disruption caused by the pandemic. We continue to progress the accreditation of Specialty Centers to provide treatment to EPP patients. From three Specialty Centers upon launch, we now have 25 accredited out of the 30 planned across the US. Over 50 private insurers –local and national -have agreed to cover the cost of treatment of SCENESSE®under Prior Authorization arrangements, acceptance as a special drug or their formulary listing."
-More Euro countries being worked on -US EPP centres now up to 25.
Wow. If they get them all working smoothly with the PA system, that will drive some seriously impressive and welcome growth.
CUV Price at posting:
$23.60 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)